The edition · Pulmonology
Start asthma biologics earlier, GLP-1s do not prevent sleep apnoea, and a new IPF option
A global registry links earlier severe-asthma biologic initiation to better outcomes, GLP-1 agonists do not prevent incident sleep apnoea in diabetes, a chemo-free TKI-radiotherapy strategy shines in EGFR-mutant stage III lung cancer, and TETON supports inhaled treprostinil in idiopathic pulmonary fibrosis.
The edition in brief
Five findings for pulmonologists. A 9,241-patient global severe-asthma registry analysis found that the longer biologics were delayed, the lower the odds of later remission and lung-function recovery, supporting a shift from reserving biologics to preserving lung function by starting them earlier. A large UK cohort found GLP-1 receptor agonists did not reduce incident obstructive sleep apnoea versus weight-neutral DPP-4 inhibitors in type 2 diabetes (hazard ratio 1.07), tempering expectations that weight loss alone prevents it. The small phase 3 ADVANCE trial of a chemotherapy-free aumolertinib-plus-radiotherapy strategy in EGFR-mutant unresectable stage III NSCLC showed a striking progression-free survival gain (34.0 vs 7.4 months), though only 43 patients were randomised before early termination, with a real-world cohort supporting it. A pearl covers recognising idiopathic pulmonary fibrosis early. The practice-changer is the combined TETON-1 and TETON-2 analysis: inhaled treprostinil slowed forced vital capacity decline over 52 weeks (between-group difference 111.8 ml) and delayed clinical worsening and exacerbations, supporting it as a treatment option in IPF.
Severe asthma: start biologics earlier, not as a last resort
Consider starting biologics earlier in severe asthma, before fixed lung-function loss and heavy steroid exposure accrue, rather than reserving them as a last resort.
GLP-1 agonists did not prevent new sleep apnoea in diabetes
Do not rely on GLP-1 agonists to prevent new obstructive sleep apnoea in diabetes; their value is in weight, glycaemia and reducing severity in diagnosed OSA.
A chemo-free TKI-plus-radiotherapy strategy in EGFR-mutant stage III lung cancer
Consider a chemo-free aumolertinib-plus-radiotherapy strategy for EGFR-mutant unresectable stage III NSCLC as a promising option, recognising the randomised evidence is small.
Suspect and refer idiopathic pulmonary fibrosis early
When bibasal Velcro-like crackles accompany unexplained progressive breathlessness, order high-resolution CT and refer to an ILD service rather than assuming age, heart failure or COPD.
TETON: inhaled treprostinil slows decline in idiopathic pulmonary fibrosis
Consider inhaled treprostinil as a treatment option in idiopathic pulmonary fibrosis to slow lung-function decline and delay worsening, weighing cough as the main tolerability issue.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free